Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Moderna (NasdaqGS:MRNA) with a Underperform ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.09% of ...

Wolfe Research initiated coverage of Veracyte (VCYT) with an Outperform rating and $50 price target Published first on TheFly – the ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research has recently raised Warner Bros Discovery Inc (WBD) stock to Peer Perform rating, as announced on November 11, 2024, according to Finviz. Earlier, on August 13, 2024, Bernstein had ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

Investing.com - Wolfe Research has upgraded shares of Warner Bros. Discovery (NASDAQ:WBD) to Peer Perform from Underperform following its Q3 results last week, and assigned a fair value range of $ ...

Wolfe Research downgraded Altair to Peer Perform from Outperform. The firm notes on Wednesday, Altair (ALTR) announced that it has reached an agreement to be acquired by Siemens (SIEGY), for $113 ...

周五，Wolfe Research对诊断公司Veracyte, Inc (NASDAQ:VCYT)的股票进行了首次评级，给予"优于大市"评级，目标价为$50.00。该研究机构强调了Veracyte自2021年以来显著的收入增长和毛利率扩张。据该研究机构称，Veracyte的收入已翻倍，毛利率提高了约500个基点。 该公司有望在本年度实现9000万至1亿美元的调整后EBITDA。Wolfe Rese ...

周四，Wolfe Research开始对Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI)的股票进行覆盖，给予同业表现评级。该公司强调了Maravai LifeSciences的几个积极方面，包括其同类最佳的产品、提高客户效率的作用、高比例的耗材收入，以及具有显著改善潜力的可观利润率。 分析师指出，该公司面临的主要挑战在于其大部分收入来自mRNA生物制 ...